Home

Health Care

Victory on Biosimilars in Senate HELP Committee - But Still a Long Way from the Finish Line
The Washington Post: Special section on biotechnology
Health Reform Debate Heats Up and Slows Down

The health reform debate is heating up and, in at least one respect, slowing down a bit.

The Future of Healthcare: Personalized Medicine
Podcast: Bioinformatics Allows a Virtual Tour of the Human Body
Preparing Before the Storm: The Reimbursement Policy Disaster

During Tuesday's panel, we had the opportunity to lay the foundation of Medicare reimbursement policy, and discuss current trends and how health reform my impact reimbursement for biotechnology therapies in the future.

Developing Drugs for Rare Diseases
Current Challenges in Managing Relationships Between Industry and Physicians
Tricia Brooks and James Trussell Discuss Stem Cell Research and Parkinson's Cures

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

Podcast: Elton John talks AIDS
The Right Fit for Companion Technologies
Asia as the Biosimilar Launch Pad
Financial Conflicts of Interest in Medical Research: Problem or Problem of Perception?
Developing drugs and companion diagnostics
op-ed: Health Disparities – An Issue for Health Professionals and Patients

Letters, Testimony & Comments

PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
Immunogenicity: BIO Comments on Draft Guidance on Immunogenicity Assessment for Therapeutic Protein Products
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Sunshine: BIO Files Comments on Estimated Burden of complying with Section 6002 of the Affordable Care Act (“the Sunshine Act”)
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...
More Press Releases →